Seagen Inc.: Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
- Data Accepted for Presentation at ESMO World Congress on Gastrointestinal Cancer - Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical